Evidence map›Paper›PMID 37346749›Full record

ArticleFrontiers in microbiology2023

Pretreatment with

Qiong Lin, Wu-Juan Hao, Ren-Min Zhou, Cui-Lan Huang, Xu-Yang Wang, Yan-Shan Liu, Xiao-Zhong Li

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Gut microbes · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Modulating effects ofFrontiers in microbiology · 2025
    Article
  7. Article
  8. Article
  9. Probiotics: Shaping the gut immunological responses.World journal of gastroenterology · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Qiong Lin *Nephrology and Immunology Department, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
Wu-Juan Hao *Department of Digestive, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Ren-Min ZhouDepartment of Digestive, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Cui-Lan HuangNanjing Medical University, Nanjing, Jiangsu, China.
Xu-Yang WangNanjing Medical University, Nanjing, Jiangsu, China.
Yan-Shan LiuDepartment of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Xiao-Zhong LiNephrology and Immunology Department, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
Jiangnan University · CNNanjing Medical University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Inflammatory bowel disease (IBD) is a chronic lifelong inflammatory disease. Probiotics such as Methods: In the present study, we pretreated C57BL/6J mice with Results: We found that pretreatment of Conclusion: Our study demonstrates the impact of BAA2573 on the gut microbiota and reveals a possible novel adjuvant therapy for IBD patients.

Indexed as

bifidobacterium longumDSS-induced colitisgut microbiotainflammatory bowel diseasemetabolitesprobiotics

Identifiers

PMID37346749
PMCPMC10280014
OpenAlexW4379534603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.